Long-term weight loss interventions for type 2 diabetes in adults

Norris, S. L.; Avenell, Alison; Bowman, Barbara A.; Brown, Todd T.; Gregg, Edward W.; Serdula, Mary K.

doi:10.1002/14651858.cd004095

Cited by 70 publications

(97 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, translation into routine practice has generally less effect on T2DM risk reduction 45 . In a metaanalysis of randomised controlled trials, HbA1c changes in patients with T2DM corresponded to those in bodyweight and both changes were overall rather small 46 . However, while the overall improvements are limited from a population standpoint, some individuals may achieve substantial improvements in multiple metabolic parameters.…”

Section: Diet and Physical Activity Combinationmentioning

confidence: 98%

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Scheen

Gaal

2014

The Lancet Diabetes & Endocrinology

175

131

View full text Add to dashboard Cite

New glucose-lowering therapies, especially glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, offer advantages over traditional antidiabetic agents by promoting weight loss while improving glucose control. . The present review will explore the overlapping pathophysiology and also how the various therapies can, alone or in combination, combat the 'dual burden' of obesity and T2DM. Word count: 249

show abstract

Section: Diet and Physical Activity Combinationmentioning

confidence: 98%

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Scheen

Gaal

2014

The Lancet Diabetes & Endocrinology

175

131

View full text Add to dashboard Cite

show abstract

“…These results, however, are often difficult to sustain, particularly in real-world clinical settings. Weight loss as a result of non-pharmacologic interventions is often a temporary phenomenon, and as weight is regained, glycaemic and cardiovascular benefits associated with weight reduction tend to diminish [126,127].Antiobesity Agents. Only two agents, sibutramine and orlistat, are currently approved for long-term use in the treatment of obesity; both agents can be used in individuals with a BMI ≥ 27 with comorbidities or >30 without comorbidities [128].…”

mentioning

confidence: 99%

Diabesity: therapeutic options

Colagiuri¹

2010

Diabetes Obesity Metabolism

102

View full text Add to dashboard Cite

A pathogenic relationship exists between type 2 diabetes and obesity. Over the last decade, the escalation in diabetes cases has paralleled the rapid increase in obesity rates, constituting a global health crisis. Environmental risk factors attributed to the global increase in obesity include the consumption of high-calorie, high-fat foods and inadequate physical activity. Obese individuals may also have a genetic predisposition for obesity. Both diabetes and obesity confer an elevated risk of developing a range of complications and comorbidities, including cardiovascular disease, hypertension and stroke, which can complicate disease management. This review examines the aetiology of the linkages between diabetes and obesity and the range of available therapies. Recent clinical evidence substantiating the efficacy and safety of incretin-based antidiabetic therapies is analysed, in addition to data on antiobesity therapeutic strategies, such as antiobesity agents, behaviour modification and bariatric surgery. Glucose control is often accompanied by weight-neutral or modest weight reduction effects with DPP-4 inhibitor treatment (sitagliptin, vildagliptin, saxagliptin) and weight loss with GLP-1 receptor agonist therapy (exenatide, liraglutide). Studies of antiobesity agents including orlistat, sibutramine and rimonabant have shown attrition rates of 30-40%, and the long-term effects of these agents remain unknown. Bariatric surgical procedures commonly performed are laparoscopic adjustable banding of the stomach and the Roux-en-Y gastric bypass, and have produced type 2 diabetes remission rates of up to 73%. Therapeutic strategies that integrate glycaemic control and weight loss will assume greater importance as the prevalence of diabetes and obesity increase. Keywords: DPP-4, exenatide, GLP-1 analogue, human, incretin, liraglutide, once-daily, type 2 diabetes mellitus Date submitted 2 June 2009; date of first decision 2 November 2009; date of final acceptance 4 November 2009 IntroductionThe term 'diabesity', coined by Sims and colleagues [1] in the 1970s, describes the strong link between type 2 diabetes and obesity [1,2]. As evidence of this pathogenic interrelationship continues to accumulate, so does the appearance of the term in the clinical literature. A large body of clinical evidence attests to the relationship between being overweight or obese and being at an elevated risk for development of type 2 diabetes [3][4][5][6][7]. The risk escalates with the degree of excess weight, increasing threefold with a body mass index (BMI) of 25.0-29.9 kg/m 2 and 20-fold with a BMI over 30 kg/m 2 [4]. In particular, abdominal fat accumulation exacerbates insulin resistance and confers a strong, independent risk of developing diabetes [8]. Global diabetes prevalence is estimated at 171 million and is projected to more than double, to 366 million, by 2030 [9]. Countries with the highest numbers of diabetes cases include India, China, USA, Indonesia and Japan [9][10][11]. The greatest relative increases in diabetes incide...

show abstract

“…Goddijn et al 31 investigated the association between the improvement of the glycemic control (HbA1c less than 8%) and the quality of life in type 2 diabetic patients during 1 years of treatment and showed positive association between these variables. A metanalysis study demonstrated that reductions above 0.3% of the glycated hemoglobin are clinically beneficial for controlling diabetes and, as consequence, improved the QOL of the carrier 32 .…”

Section: Discussionmentioning

confidence: 99%